Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Mexico / NCT07262320
Recruiting Observational

Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America

NCT07262320 · tracked via the Priya Life Science Mexico tracker
Sponsor
University of Alabama at Birmingham
Phase
Observational
Started
2026-03-01
Last updated
2026-03-12

Condition(s) studied

DialysisCritically Ill Acute Kidney InjuryRenal Replacement Therapy for Acute Kidney Injury in ICUAcute Kidney InjuryRenal Replacement TherapyAKI

Study summary

This is an international, multicenter, observational study aimed at investigating acute kidney injury requiring renal replacement therapy (AKI-RRT) in Latin American countries. The main questions this study aims to answer are:

* What is the epidemiology, outcomes, and processes of care for patients with AKI-RRT in Latin America?
* How do outcomes differ across different countries in Latin America?
* What factors (demographics, clinical, socioeconomic) influence outcomes in patients with AKI-RRT in Latin America?

The main aims of this study are to:

* Establish a comprehensive database containing clinical, laboratory, treatment, process, and outcome data of patients with AKI-RRT in Latin America
* Describe current epidemiology of AKI-RRT in Latin America
* Compare processes of care and outcomes across different countries in Latin America
* Provide data resources to facilitate and promote clinical research in AKI-RRT

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patient (≥18) admitted to the ICU * First ICU admission during current hospitalization * Diagnosis of acute kidney injury stage 3 according to KDIGO guidelines * RRT initiated no earlier than 3 days before or no later than 7 days after ICU admission Exclusion Criteria: * Transfer from outside hospital with ongoing RRT * RRT exposure of less than 2 days (if CRRT or PD was provided) or less than 2 HD/SLED sessions * Kidney failure (ESRD) patients on maintenance dialysis * Kidney transplant recipients * Previous or new diagnosis of glomerulonephritis

Primary outcome measure(s)

  • In-hospital mortality — From enrollment to hospital discharge or 90 days (whichever occurs first)
    The variable is coded as 1 = deceased and 0 = alive by the time of hospital discharge

Trial sites (15)

FacilityCityRegionStatus
Hospital Obrero No 2 Cochabamba Bolivia Recruiting
Ana Nery Hospital Bahia Brazil Not Yet Recruiting
Hospital Sao Lucas da PUCRS Porto Alegre Brazil Not Yet Recruiting
Hospital das Clínicas da Universidade de São Paulo São Paulo Brazil Not Yet Recruiting
Hospital Las Higueras Talcahuano Chile Not Yet Recruiting
Fundación Cardioinfantil Bogotá Colombia Recruiting
Hospital San Jose de Popayan Popayán Colombia Recruiting
Hospital General de la Plaza de la Salud Santo Domingo Dominican Republic Recruiting
DIALNEF Quito Ecuador Not Yet Recruiting
Instituto Guatemalteco de Seguridad Social Guatemala City Guatemala Not Yet Recruiting
Hospital Civil de Guadalajara Guadalajara Mexico Recruiting
Hospital General de México Dr Eduardo Liceaga Mexico City Mexico Not Yet Recruiting
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City Mexico Recruiting
Hospital Universitario "José Eleuterio González" Monterrey Mexico Recruiting
Hospital Nacional Arzobispo Loayza Lima Peru Recruiting

More University of Alabama at Birmingham trials in Mexico

Congenital Syphilis Treatment Trial (CONSISTENT) in Neonates Starting soon

Other trials for the same condition

Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 Enrolling by invitation
Nafamostat Efficacy in Phase 3 Registrational CRRT Study Recruiting
Volume Removal Intolerance During Net Ultrafiltration in Acute Kidney Injury Patients Recruiting
Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07262320 on ClinicalTrials.gov ↗ ← All trials in Mexico